September 26, 2021, Boston, USA - Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific anti...
September 23,2021. Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) has been granted by the UK’...
Luye Pharma Group announced today that a Phase III clinical trial of its innovative formulation for the treatment of prostate cancer, Goserelin Acetate Extended-release Microspheres for Injection (LY0...
Luye Pharma Group today announced that Boyounuo (Bevacizumab Injection), an oncology biologic developed in-house by its subsidiary Boan Biotech, has been approved by China’s National Medical Pro...
The global COVID-19 pandemic poses a serious threat to physical health and has wide-ranging implications for mental health worldwide. At the third Asia Pacific Psychiatry Symposium, held online on Jun...
Luye Pharma Group’s subsidiary Boan Biotech recently published research results for its innovative in-house bispecific antibody BA1202 (CEA/CD3 bispecific T-cell engager) inAntibody Therapeutics...
Dear Business Partners & Customers,To accommodate our growing business, Luye Life Sciences Group Shanghai Office will be relocated from Building 12, Shanghai Business Park III, No.1036 Tianlin Roa...
Luye Pharma Group announced that the marketing authorization application for the company’s in-house developed Class 1 new drug Anshufaxine Hydrochloride Extended-Release Tablets (LY03005) has be...
Luye Pharma Group today announced the successful completion of the Decentralised Registration Procedures (DCPs) for its Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD). With the end of proc...
Luye Pharma Group announced that its biopharmaceutical drug 博优诺®(Bevacizumab Injection), developed by the Group’s holding subsidiary Boan Biotech, has received marketing authorization from Ch...
TOP